The BCL2 gene, known to inhibit apoptosis, was also upregulated in our resistant cells, a phenomenon commonly observed in liver cancer following treatment with other drugs like sorafenib and cabozantinib [26] The concomitant upregulation of FOXA1 and BCL2 suggests that doxorubicin may be triggering a mitochondrial apoptotic pathway in liver cancer cells. This evidence concerns the gene FOXA1 and liver cancer.